Last update 20 Sep 2024

Esmolol Hydrochloride

Last update 20 Sep 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(±)-esmolol, (±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate, 3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester

+ [16]

Target

β1-adrenergic receptor

Mechanism

β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [1]

Active Indication

Diabetic foot ulcerVentricular ArrhythmiaHypertension+ [2]

Inactive Indication-

Originator Organization

Baxter International, Inc.

Active Organization

Baxter Healthcare Corp.

NovaLead Pharma Pvt Ltd.

Maruishi Pharmaceutical Co., Ltd.

+ [1]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (31 Dec 1986),

HypertensionTachycardia, SupraventricularTachycardia

Regulation-

Structure

Molecular FormulaC16H26ClNO4

InChIKeyGEKNCWBANDDJJL-UHFFFAOYSA-N

CAS Registry81161-17-3

173

Clinical Trials associated with Esmolol Hydrochloride

CTRI/2024/07/070665 / Not yet recruitingNot ApplicableIIT

Attenuation of Haemodynamic Responses to Laryngoscopy and Endotracheal Intubation (Before and Elective Surgery): A Comparative Study Between Intravenous Esmolol and 4% Lignocaine Nebulisation - NIL

Start Date01 Aug 2024

Sponsor / Collaborator-

NCT06522594 / RecruitingPhase 2

Randomized Embedded Multifactorial Adaptive Platform in ExtraCorporeal Membrane Oxygenation - Beta Receptor Modulation Trial

In this phase 2, single center, randomized clinical pilot trial, investigators will study the effect of a strategy involving a reduction of beta receptor (BR) stimulation (by decreasing dobutamine dosages) and subsequent BR inhibition (through ultra-short acting betablockers), versus a (routine) strategy with continued BR stimulation through dobutamine infusion, on heart rate in patients with cardiogenic shock due to left- or bi-ventricular failure being supported by V-A ECMO.

Start Date01 Jun 2024

Sponsor / Collaborator

Erasmus Medical Center (Private Equity)

NCT06291363 / RecruitingPhase 4IIT

Impact of Continuous Intraoperative Administration of Esmolol on Nociception Level-guided Control of Nociception. The EsmoNOL Randomized Controlled Trial

This study aims to evaluate esmolol's perfusion impact during induction and maintenance of general anesthesia, using Nociception-Level-guided control of nociception, in adult patients undergoing laparoscopic and lower abdominal surgery, on intraoperative remifentanil consumption and postoperative pain in the Post-Anesthesia Care Unit.

Start Date16 Apr 2024

Sponsor / Collaborator

CIUSSS de lEst-de-lÎle-de-Montréal

100 Clinical Results associated with Esmolol Hydrochloride

100 Translational Medicine associated with Esmolol Hydrochloride

100 Patents (Medical) associated with Esmolol Hydrochloride

1,564

Literatures (Medical) associated with Esmolol Hydrochloride

01 Jan 2024·The American journal of emergency medicine

Utility of nicardipine in the management of hypertensive crises in adults with reduced ejection fractions

Article

Author: Saleh, Sahba ; Holzmann, Sarah ; Ibarra, Francisco ; Dang, Thu ; Kapoor, Vishali ; Shah, Saumya ; Fountain, Cade

BACKGROUND:

Nicardipine is commonly used in the management of hypertensive crises, except those involving cardiac contractility defects despite its ability to reduce afterload and pulmonary congestion. Consequently, there is limited literature evaluating nicardipine's role for this indication. The purpose of this study was to evaluate the efficacy and safety of nicardipine in adults with reduced ejection fractions presenting with acute heart failure with hypertension (AHF-H).

METHODS:

This was a retrospective study conducted at an academic Level 1 trauma center with an annual Emergency Department (ED) volume surpassing 100,000. The purpose of this study was to determine the efficacy and safety of nicardipine in adults with reduced ejection fractions presenting to the ED with AHF-H. Efficacy was determined by achievement of the physician prescribed blood pressure target range. The primary safety endpoints included the number of individuals who experienced bradycardia (< 60 beats per minute, bpm) or hypotension (systolic blood pressure, SBP, < 90 mmHg) while receiving nicardipine and for up to 15 min after its discontinuation. Patients were included if they were ≥ 18 years of age, received a continuous intravenous nicardipine infusion within six hours of presenting to the ED, and had an ejection fraction ≤ 40% per an echocardiogram obtained within three months of the study visit. Pregnant and incarcerated patients were excluded.

RESULTS:

Of the 500 patient charts reviewed, 38 met inclusion criteria. The median (interquartile, IQR) ejection fraction and brain natriuretic peptide (BNP) were 35% (25-40) and 731 pg/nL (418-3277), respectively. The median baseline heart rate and SBP were 90 bpm and 193 mmHg, respectively. The median physician specified SBP goal was 160 mmHg and all patients met this endpoint in a median time of 18 min. One (2.6%) patient in the total population developed both hypotension and bradycardia. This patient had an ejection fraction of 20%, was intubated, and received nicardipine in addition to esmolol for an aortic dissection without experiencing an adverse event until 30 min after dexmedetomidine was initiated.

CONCLUSION:

In this non-interventional study evaluating the use of nicardipine in patients with reduced ejection fractions presenting to the ED with AHF-H, nicardipine was found to be safe and effective. To our knowledge this is the largest study to date evaluating nicardipine in this patient population and positively contributes to the existing literature.

01 Jan 2024·American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Precipitation of hyponatremia and seizures by esmolol in sterile water formulation

Article

Author: Zavala, Sarah ; Roels, Cathrine ; Kaminsky, Nicole

Abstract:

Purpose:

Acute hyponatremia can lead to severe neurological symptoms such as confusion, obtundation, seizures, coma, and respiratory depression, contributing to increased morbidity and mortality. Patients with acute hyponatremia should be evaluated based on volume status and serum osmolality to determine potential causes and appropriate treatment. The aim of this case report is to illustrate the importance of using a multidisciplinary approach to evaluate medication formulation and the potential impact on a patient’s clinical course.

Summary:

A 34-year-old male was admitted for type A aortic dissection and was treated with an esmolol infusion and underwent operative repair. Two days after initiation of esmolol, the patient developed seizures and antiepileptics were initiated. The patient’s serum sodium concentration was found to have decreased by a total of 14 mEq/L since admission. The patient had received more than 6 L of esmolol formulated in sterile water over the course of 2 days. The esmolol infusion was converted to another antihypertensive agent, and 0.9% sodium chloride injection was initiated, after which the serum sodium concentration began to recover. No further seizures were observed on continuous electroencephalography, and all antiepileptic drugs were discontinued with no seizure activity.

Conclusion:

The esmolol product utilized in this case was formulated in 250 mL of sterile water, which is suspected to have contributed to the patient’s hyponatremia. It is important to be aware of the formulation and excipients of medications and their potential for adverse effects.

01 Dec 2023·Trauma case reports

Non-operative management strategy for blunt pulmonary artery pseudoaneurysm: A case report

Author: Kuruvilla, Kevin ; McNickle, Allison G ; Fraser, Douglas R ; Feery, Declan A

Traumatic pulmonary artery pseudoaneurysms (PAP) are rare findings and are often associated with penetrating trauma to the chest. We present a case of a pulmonary artery pseudoaneurysm following blunt trauma. A 49-year-old man presented after a motor vehicle collision. Contrast enhanced computed tomography scans of the neck, chest, abdomen, and pelvis were obtained demonstrating a proximal right pulmonary artery pseudoaneurysm, small volume hemopericardium, left first rib fracture, and focal non-flow limiting dissection of left subclavian artery. For the management of right PAP, we adopted a non-operative management strategy with an esmolol infusion for strict heart rate and blood pressure control. An echocardiogram was obtained the next day revealing no cardiac tamponade. Angiography of the chest was done after 24 h which showed stable appearance of the right PAP and hemopericardium. Patient was discharged home on hospital day 11.

News (Medical) associated with Esmolol Hydrochloride

04 Jan 2024

·www.biospace.com

Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023

More new product innovations in 2023, as compared to 26 in 2022 13 new products launched in the fourth quarter of 2023 BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) today announces that it has launched 39 new retail and injectable medicines in 2023, as compared to 26 new launches in 2022. In the fourth quarter of 2023, Amneal launched 13 new products, including 5 injectables. New injectable products added include potassium phosphate vials, tranexamic acid and esmolol intravenous bags. These launches provide a strong foundation for higher injectable revenues going forward. In addition, Amneal launched several key new retail products in the fourth quarter, including spironolactone suspension with 180-day exclusivity, valsartan and hydrochlorothiazide tablets, and icosapent capsules. “We are pleased to have brought an impressive number of new products to market in 2023,” said Dr. Srinivas Kone, Senior Vice President, Generics R&D. “Our R&D portfolio prioritizes complex and high-value products that provide better access to affordable medicines for providers and patients.” About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit . Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations, including international expansion; expected or estimated operating results and financial performance; the Company’s growth prospects and opportunities as well as its strategy for growth; product development and launches; the successful commercialization and market acceptance of new products, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our ability to manage our growth through acquisitions and otherwise; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; our ability to complete the proposed holding company reorganization on the anticipated timeline or at all and to realize the expected benefits of such reorganization; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our ability to secure satisfactory terms when negotiating a refinancing or other new indebtedness; our dependence on third-party agreements for a portion of our product offerings; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties, including recent events affecting the financial services industry; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our ability to attract, hire and retain highly skilled personnel; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. View source version on businesswire.com: Contacts Investors: Anthony DiMeo Head of Investor Relations anthony.dimeo@amneal.com Source: Amneal Pharmaceuticals, Inc. View this news release online at:

20 Dec 2022

·www.biospace.com

Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

- 8 new product launches in Q4 closes out another successful year of innovation - First approval of a large volume bag product signals further expansion of injectables business BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Company has successfully launched 26 new generic products in 2022. In the fourth quarter of 2022, the Company launched 8 new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal sprays, and prednisolone sodium phosphate oral solution. “2022 was another successful year of innovation for Amneal. Across the portfolio we continue to innovate, further expand our portfolio of essential medicines, and drive incremental impact and benefit for health care professions and their patients. Looking to 2023, we expect more than 30 new product launches,” said Chirag Patel and Chintu Patel, Amneal Co-Chief Executive Officers. In addition, Amneal also announced it received Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (“FDA”) for its first large volume bag, esmolol hydrochloride in sodium chloride injection. Harsher Singh, SVP for Amneal Biosciences, stated, “We are seeing continued momentum in expanding our injectables business. We are excited about this first ready to use bag approval utilizing one of our new manufacturing sites and look forward to more over the coming months.” Esmolol hydrochloride in sodium chloride injection is indicated for tachycardia. For full prescribing information, see package insert located here. According to IQVIA®, U.S. annual sales for this product for the 12 months ended October 2022 were $57 million. About Amneal Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit . Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance, the Company’s growth prospects and opportunities as well as its strategy for growth; product development and launches; the successful commercialization and market acceptance of new products, and expenditures. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry, in general, specifically from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our ability to manage our growth through acquisitions and otherwise; our dependence on the sales of a limited number of products for a substantial portion of our total revenues; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods and any associated supply chain disruptions; existing and future legal proceedings, the outcome of which are uncertain and may divert management resources and require us to incur substantial defense or settlement payments and costs; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; the impact of severe weather; the impact of the ongoing COVID-19 pandemic, and the emergence of variant strains; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to FDA product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; the impact of global economic conditions, including any economic effects stemming from adverse geopolitical events, an economic downturn, inflation and rising interest rates; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Drug Approval

100 Deals associated with Esmolol Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00644	Esmolol Hydrochloride	C07AB09	DB00187

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic foot ulcer	IN	NovaLead Pharma Pvt Ltd.	24 Apr 2024
Ventricular Arrhythmia	JP	Maruishi Pharmaceutical Co., Ltd.	08 Oct 2002
Hypertension	US	Baxter Healthcare Corp.	31 Dec 1986
Tachycardia	US	Baxter Healthcare Corp.	31 Dec 1986
Tachycardia, Supraventricular	US	Baxter Healthcare Corp.	31 Dec 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Foot	Phase 2	US	NovaLead Pharma Pvt Ltd.	01 Feb 2014
Diabetic Foot	Phase 2	IN	NovaLead Pharma Pvt Ltd.	01 Feb 2014
Diabetic Foot	Phase 2	MY	NovaLead Pharma Pvt Ltd.	01 Feb 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01113515 (CTgov)	Phase 1/2	Diabetic foot ulcer	44	Placebo gel (Placebo)	dvzidohrtm(mzkysnywnx) = nbctmyljjn tbhvpxrksk (snqryihloj, jphybsqsnm - nxbuabxufg) View more	-	20 May 2024
				Esmolol hydrochloride (Galnobax 20% QD)	dvzidohrtm(mzkysnywnx) = chprdsztjx tbhvpxrksk (snqryihloj, bmxcfijjkc - rttlqhlbvk) View more
NCT03998436 (CTR/2018/11/016295, CTgov)	Phase 3	Diabetic foot ulcer	176	Esmolol Hydrochloride (Galnobax® 14% Gel Plus SoC)	qfmzlgaxek(wqfbqjxmdj) = asyjdopeyp uqfdrbvolq (mxqaafilzg, jnvhfgktkf - rtyieofrmk) View more	-	22 Sep 2023
				Only Standard of Care (SoC Only)	qfmzlgaxek(wqfbqjxmdj) = nyzsjidnou uqfdrbvolq (mxqaafilzg, tcejikqlsb - yqbaacqpfh) View more
NCT03998436 (CTR/2018/11/016295, Pubmed)	Phase 3	Diabetic foot ulcer	176	Esmolol with SoC	ocznttsvop(hwfzygjmuv) = jcepeemxzj avjcasnumy (xuyarotgwz ) View more	-	01 May 2023
				Topical Esmolol Hydrochloride (SoC only)	ocznttsvop(hwfzygjmuv) = cbktzppehf avjcasnumy (xuyarotgwz ) View more
Pubmed	Phase 1/2	Diabetic foot ulcer	-	Galnobax 14%	fodrhxifrp(ktxdyzpwoy) = emlkbkonuu peaugzhyou (aezukucddf ) View more	-	16 Oct 2022
				Galnobax 20%	fodrhxifrp(ktxdyzpwoy) = olhstdxiue peaugzhyou (aezukucddf ) View more
NCT02369900 (Pubmed)	Phase 2	Shock, Septic	40	Esmolol	gonofapsnq(ncabwecviu) = iqztujhlzl bojvvqmqak (uocenpybtz )	-	27 Dec 2021
				Placebo	gonofapsnq(ncabwecviu) = zijuvjfeza bojvvqmqak (uocenpybtz )
NCT02369900 (CTgov)	Phase 2	Shock, Septic \| Hypotension \| Tachycardia	40	Esmolol (Esmolol Infusion)	ointctrohy(qsezxevzef) = zvqfkfnywf szgvmbrnwt (nvziyafzke, bfjdfzoqfe - tjefophsby) View more	-	28 Jun 2021
				saline (Standard Care, Saline)	ointctrohy(qsezxevzef) = tlnvnflzfz szgvmbrnwt (nvziyafzke, istdmjzfae - szenloifzr) View more
NCT02466542 (Pubmed \| Eur J Anaesthesiol)	Phase 4	Pain	-	Esmolol infusion	ngtkfvdrtg(ntanqrhpfs) = jtoeeportc kxquyujsfj (hprkgfkdsi, -13.4 to -0.31)	Positive	08 Apr 2021
NCT03661346 (CTgov)	Phase 2	Hemorrhage \| Chronic sinusitis	28	Esmolol (Esmolol)	pphjigstzx(sgkqpxmvhe) = mnnirwelnx nkfllsunaf (cqafzmbhbv, yzycvvuroo - echudysovi) View more	-	08 Feb 2021
				Labetalol (Labetalol)	pphjigstzx(sgkqpxmvhe) = wvaheunmqp nkfllsunaf (cqafzmbhbv, bkmxklerbo - ewwskarlqh) View more
NCT02068287 (ESMOSEPSIS, Pubmed \| Crit Care) Manual	Phase 2	Shock, Septic	9	Esmolol	wmhgtnubru(koizpjealw) = decrease from 4.2 to 2.9 l/min/m-2 bihxgbbmxy (tloojxlhhn ) View more	Positive	07 Jan 2021
NCT01114971 (CTgov)	Phase 4	Pain, Postoperative	75	Esmolol+Labetalol (Fentanyl)	iqevmbcwaj(zojgdkiyyb) = ucvvwhqhlw gzajchviwn (hduuyxzyyy, uvnvrchyvb - mfbqequkiv) View more	-	20 Feb 2020
				Esmolol+Fentanyl (Labetalol)	iqevmbcwaj(zojgdkiyyb) = byahpguknm gzajchviwn (hduuyxzyyy, sqqfwzgmoj - gketmrgyen) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis